{"id":"https://openalex.org/W4388072017","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0449","title":"449 Polygenic risk scores for liver injury are associated with the risk for autoimmune hepatitis in patients treated with atezolizumab","display_name":"449 Polygenic risk scores for liver injury are associated with the risk for autoimmune hepatitis in patients treated with atezolizumab","publication_year":2023,"publication_date":"2023-10-31","ids":{"openalex":"https://openalex.org/W4388072017","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0449"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2023-sitc2023.0449","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0449","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.0449","pdf_url":"https://jitc.bmj.com/content/jitc/11/Suppl_1/A499.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-paper","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/11/Suppl_1/A499.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072644489","display_name":"Ashis Saha","orcid":"https://orcid.org/0000-0003-3203-2114","observed_orcids":["https://orcid.org/0000-0003-3203-2114"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashis Saha","raw_affiliation_strings":["Genentech, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067273270","display_name":"Cameron Adams","orcid":"https://orcid.org/0000-0003-2525-523X","observed_orcids":["https://orcid.org/0000-0003-2525-523X"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cameron Adams","raw_affiliation_strings":["Genentech, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068502154","display_name":"David Roe","orcid":"https://orcid.org/0000-0001-7750-3026","observed_orcids":["https://orcid.org/0000-0001-7750-3026"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Roe","raw_affiliation_strings":["Genentech, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064948585","display_name":"Mark I. McCarthy","orcid":"https://orcid.org/0000-0002-4393-0510","observed_orcids":["https://orcid.org/0000-0002-4393-0510"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark McCarthy","raw_affiliation_strings":["Genentech, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085574965","display_name":"Ira Mellman","orcid":"https://orcid.org/0000-0002-6132-7299","observed_orcids":["https://orcid.org/0000-0002-6132-7299"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ira Mellman","raw_affiliation_strings":["Genentech, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014363589","display_name":"Rajat Mohindra","orcid":"https://orcid.org/0009-0000-4233-5210","observed_orcids":["https://orcid.org/0009-0000-4233-5210"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Rajat Mohindra","raw_affiliation_strings":["F.Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F.Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084564240","display_name":"G. Scott Chandler","orcid":"https://orcid.org/0000-0001-5339-9906","observed_orcids":["https://orcid.org/0000-0001-5339-9906"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"G Scott Chandler","raw_affiliation_strings":["F.Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F.Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033829874","display_name":"Christian Hammer","orcid":"https://orcid.org/0000-0003-4548-7548","observed_orcids":["https://orcid.org/0000-0003-4548-7548"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christian Hammer","raw_affiliation_strings":["Genentech, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.21015453,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A499","last_page":"A500"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9643999934196472,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9643999934196472,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.013399999588727951,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10261","display_name":"Genetic Associations and Epidemiology","score":0.009399999864399433,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/polygenic-risk-score","display_name":"polygenic risk score","score":0.9330000281333923},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9559999704360962},{"id":"https://openalex.org/keywords/autoimmune-hepatitis","display_name":"autoimmune hepatitis","score":0.859000027179718},{"id":"https://openalex.org/keywords/alanine-aminotransferase","display_name":"alanine aminotransferase","score":0.8849999904632568},{"id":"https://openalex.org/keywords/aspartate-aminotransferase","display_name":"aspartate aminotransferase","score":1.0},{"id":"https://openalex.org/keywords/liver-injury","display_name":"liver injury","score":0.7580000162124634},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.8240000009536743},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9330000281333923},{"id":"https://openalex.org/keywords/genetic-susceptibility","display_name":"genetic susceptibility","score":0.7540000081062317},{"id":"https://openalex.org/keywords/european-ancestry","display_name":"European ancestry","score":0.4740000069141388},{"id":"https://openalex.org/keywords/whole-genome-sequencing","display_name":"whole genome sequencing","score":0.7139999866485596},{"id":"https://openalex.org/keywords/liver-cirrhosis","display_name":"liver cirrhosis","score":0.5419999957084656},{"id":"https://openalex.org/keywords/personalized-risk-prediction","display_name":"personalized risk prediction","score":0.38999998569488525}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.7708101868629456},{"id":"https://openalex.org/C2777203481","wikidata":"https://www.wikidata.org/wiki/Q786844","display_name":"Autoimmune hepatitis","level":3,"score":0.6177128553390503},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6004173755645752},{"id":"https://openalex.org/C106208931","wikidata":"https://www.wikidata.org/wiki/Q1098876","display_name":"Genome-wide association study","level":5,"score":0.587242603302002},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5188597440719604},{"id":"https://openalex.org/C2776029263","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Hepatitis","level":2,"score":0.5120120644569397},{"id":"https://openalex.org/C2777214474","wikidata":"https://www.wikidata.org/wiki/Q147778","display_name":"Cirrhosis","level":2,"score":0.4453566372394562},{"id":"https://openalex.org/C2776637226","wikidata":"https://www.wikidata.org/wiki/Q6658207","display_name":"Liver injury","level":2,"score":0.43371233344078064},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4125877022743225},{"id":"https://openalex.org/C153209595","wikidata":"https://www.wikidata.org/wiki/Q501128","display_name":"Single-nucleotide polymorphism","level":4,"score":0.3769285976886749},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.356955885887146},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.21227750182151794},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.19094225764274597},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1606132686138153},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.09413427114486694},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.0858812928199768},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.07807233929634094}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2023-sitc2023.0449","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0449","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.0449","pdf_url":"https://jitc.bmj.com/content/jitc/11/Suppl_1/A499.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:a9ad185c44b745b893e6606efca62005","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/a9ad185c44b745b893e6606efca62005","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2023-sitc2023.0449","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.0449","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.0449","pdf_url":"https://jitc.bmj.com/content/jitc/11/Suppl_1/A499.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4388072017.pdf","grobid_xml":"https://content.openalex.org/works/W4388072017.grobid-xml"},"referenced_works_count":6,"referenced_works":["https://openalex.org/W2736166064","https://openalex.org/W3113354312","https://openalex.org/W3121239749","https://openalex.org/W3134184401","https://openalex.org/W3195910217","https://openalex.org/W4206175800"],"related_works":["https://openalex.org/W4281980883","https://openalex.org/W7170043356","https://openalex.org/W4401883665","https://openalex.org/W4281639655","https://openalex.org/W4401159084","https://openalex.org/W4387752228","https://openalex.org/W4393377211","https://openalex.org/W4323320044","https://openalex.org/W7162517392","https://openalex.org/W3012305117"],"abstract_inverted_index":{"Background":[0],"Immune":[1,409,431],"checkpoint":[2,410],"inhibitor":[3],"(ICI)-induced":[4],"hepatitis":[5,103,244,278,326,337,373,619,636],"is":[6,26,377],"a":[7,47,109,186,251,258,354],"relatively":[8],"common":[9,43],"immune-related":[10],"adverse":[11],"event":[12],"(irAE).":[13],"1\u20133":[14],"Understanding":[15],"the":[16,22,51,100,122,207,300,304,311,322,334,341,344,369,381,448,465,475,548,598,610,631,647],"underlying":[17],"genetic":[18,44,90,95,149,269,312,359,522,572],"factors":[19],"contributing":[20],"to":[21,56,79,99,146,154,321,379,470],"development":[23],"of":[24,53,89,102,142,167,179,188,191,224,303,324,336,343,371,389,403,424,441,458,520,570,607,633,646],"irAEs":[25,104,327],"crucial":[27],"for":[28,127,130,133,136,140,162,241,257,267,397,427,494,518,543,568,593,644],"identifying":[29],"individuals":[30,180,329,634],"at":[31,160],"higher":[32],"risk":[33,83,101,161,246,280,323,335,370,621],"and":[34,72,138,222,247,265,281,316,365,368,374,400,444,468,496,531,539,552,581,589,602,622,640],"possibly":[35],"implementing":[36],"personalized":[37],"interventions.":[38],"Previous":[39],"studies":[40,177,305],"showed":[41],"that":[42,310],"variants":[45,91,150],"play":[46],"role":[48],"in":[49,93,144,213,299,328,447,506,536,556,586,609,624],"determining":[50],"levels":[52,318],"biomarkers":[54,446],"used":[55,113,250],"assess":[57],"liver":[58,155],"injury":[59,156],"such":[60],"as":[61,216,285,287,361,490],"serum":[62],"alanine":[63],"aminotransferase":[64,67],"(ALT),":[65],"aspartate":[66],"(AST),":[68],"gamma-glutamyl":[69],"transferase":[70],"(GGT)":[71],"alkaline":[73],"phosphatase":[74],"(ALP).4\u20135":[75],"We":[76,112,272],"therefore":[77],"aimed":[78],"investigate":[80],"whether":[81,655],"polygenic":[82,460],"scores":[84,461],"(PRS),":[85],"which":[86],"are":[87],"aggregates":[88],"tested":[92],"large-scale":[94],"association":[96,176,242,357],"studies,":[97],"contribute":[98,320],"during":[105],"treatment":[106,399],"with":[107,152,181,331,340,659],"atezolizumab,":[108],"PD-L1":[110],"inhibitor.Methods":[111],"16":[114],"previously":[115],"published":[116],"liver-injury":[117],"related":[118],"PRS":[119,169,641,651],"models":[120,170],"from":[121,201,230,391,464,474,524,574],"PGS":[123],"catalog":[124],"6:":[125],"4":[126,132,135],"ALT,":[128],"3":[129],"AST,":[131],"GGT,":[134],"ALP,":[137],"1":[139],"cirrhosis":[141],"liver,":[143],"order":[145],"determine":[147],"if":[148],"associated":[151,346,650],"susceptibility":[153],"could":[157],"identify":[158],"patients":[159,190,608,656],"ICI-induced":[163],"hepatitis.":[164],"Since":[165],"most":[166],"these":[168],"were":[171,297,657],"developed":[172,227],"based":[173],"on":[174],"genome-wide":[175],"(GWAS)":[178],"European":[182,192],"ancestry,":[183],"we":[184,249],"defined":[185],"cohort":[187],"4,917":[189],"ancestry":[193,472],"who":[194],"had":[195],"available":[196],"germline":[197],"whole-genome":[198],"sequencing":[199],"data":[200],"fifteen":[202],"atezolizumab":[203,212,660],"clinical":[204,232,383,545,549,595,599],"trials.":[205],"Among":[206],"selected":[208],"patients,":[209],"2,860":[210],"received":[211],"combination":[214],"or":[215,234,662],"monotherapy":[217],"across":[218],"various":[219],"tumor":[220],"types,":[221],"432":[223],"them":[225],"(15.1%)":[226],"hepatitis,":[228],"determined":[229],"either":[231],"diagnosis":[233],"lab":[235],"abnormalities":[236],"(table":[237,291],"1).":[238],"To":[239],"test":[240],"between":[243,277,358,618,630],"irAE":[245,279,620],"PRSs,":[248,367],"mixed":[252],"effect":[253],"Cox":[254],"model":[255],"allowing":[256],"different":[259],"baseline":[260],"hazard":[261],"per":[262],"trial":[263,546,550,596,600],"arm":[264],"controlling":[266],"5":[268],"principal":[270],"components.Results":[271],"observed":[273],"significant":[274,295,356],"associations":[275,296,617],"(FDR\u22640.05)":[276],"four":[282],"ALT":[283,315,364],"PRSs":[284,290,348,623],"well":[286],"three":[288],"AST":[289,317,366],"2).":[292],"Conversely,":[293],"no":[294],"found":[298],"control":[301],"arms":[302],"(N=2,057).":[306],"These":[307],"findings":[308],"suggest":[309],"mechanisms":[313],"regulating":[314],"partially":[319],"developing":[325,635],"treated":[330,658],"atezolizumab.":[332],"Notably,":[333],"gradually":[338],"increased":[339],"quantiles":[342,642],"significantly":[345,649],"liver-damage":[347],"(figure":[349],"1).Conclusions":[350],"Our":[351],"study":[352,508,541,558,591],"demonstrated":[353],"statistically":[355],"markers,":[360],"represented":[362],"by":[363,430,654],"atezolizumab-associated":[372],"further":[375],"work":[376],"warranted":[378],"characterize":[380],"potential":[382],"impact.References":[384],"Haanen":[385],"et":[386,407,421,438,455,484],"al.":[387,408,422,439,456,485],"Management":[388],"toxicities":[390],"immunotherapy:":[392],"ESMO":[393],"Clinical":[394],"Practice":[395],"Guidelines":[396],"diagnosis,":[398],"follow-up.":[401],"Annals":[402],"Oncology,":[404],"2017;":[405],"28:iv119-iv142.Remash":[406],"inhibitor-related":[411],"hepatotoxicity:":[412],"A":[413],"review.":[414],"World":[415],"J":[416,434,479],"Gastroenterol.":[417],"2021;":[418,436,453,501],"27(32):":[419],"5376\u20135391.Cho":[420],"Analysis":[423],"Risk":[425],"Factors":[426],"Hepatotoxicity":[428],"Induced":[429],"Checkpoint":[432],"Inhibitors.":[433],"Immunother.":[435],"44(1):16\u201321.Sinnott-Armstrong":[437],"Genetics":[440],"35":[442],"blood":[443,526,576],"urine":[445],"UK":[449,466],"Biobank.":[450],"Nature":[451,499],"Genetics.":[452,500],"53:185\u2013194.Priv\u00e9":[454],"Portability":[457],"245":[459],"when":[462],"derived":[463],"Biobank":[467],"applied":[469],"9":[471],"groups":[473],"same":[476],"cohort.":[477],"Am":[478],"Hum":[480],"Genet.":[481],"2022;":[482],"109:12\u201323.Lambert":[483],"The":[486],"Polygenic":[487],"Score":[488],"Catalog":[489],"an":[491,510,560],"open":[492],"database":[493],"reproducibility":[495],"systematic":[497],"evaluation.":[498],"53:420\u2013425.Ethics":[502],"Approval":[503],"Patients":[504,554],"included":[505,555],"this":[507,557],"signed":[509,559],"informed":[511,516,561,566],"consent":[512,517,562,567],"form":[513,563],"(ICF),":[514,564],"providing":[515,565],"analysis":[519,569],"inherited":[521,571],"variation":[523,573],"whole":[525,575],"samples.":[527,577],"Ethics":[528,578],"Committees":[529,579],"(EC)":[530,580],"Institutional":[532,582],"Review":[533,583],"Boards":[534,584],"(IRB)":[535,585],"each":[537,540,544,587,590,594,645],"country":[538,588],"site":[542,592],"approved":[547,597],"protocol":[551,601],"ICF.Consent":[553],"ICF.Abstract":[603],"449":[604,614,627],"Table":[605,615],"1Number":[606],"safety":[611],"evaluable":[612],"populationAbstract":[613],"2Significant":[616],"atezolizumab-treated":[625],"patientsAbstract":[626],"Figure":[628],"1Relationship":[629],"proportion":[632],"(y-axis,":[637],"cyan":[638],"colored)":[639],"(x-axis)":[643],"seven":[648],"(rows),":[652],"categorized":[653],"(right)":[661],"not":[663],"(left).":[664]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-11-01T00:00:00"}